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ABSTRACT
Anti-cancer drug discovery efforts to directly inhibit the signal transducer and 
activator of transcription 3 (STAT3) have been active for over a decade following the 
discovery that 70% of cancers exhibit elevated STAT3 activity. The majority of research 
has focused on attenuating STAT3 activity through preventing homo-dimerization by 
targeting the SH2 or transcriptional activation domains. Such dimerization inhibitors 
have not yet reached the market. However, an alternative strategy focussed on 
preventing STAT3 DNA-binding through targeting the DNA-binding domain (DBD) 
offers new drug design opportunities. Currently, only EMSA and ELISA-based methods 
have been implemented with suitable reliability to characterize STAT3 DBD inhibitors. 
Herein, we present a new orthogonal, fluorescence polarization (FP) assay suitable 
for high-throughput screening of molecules. This assay, using a STAT3127-688 construct, 
was developed and optimized to screen molecules that attenuate the STAT3:DNA 
association with good reliability (Z’ value > 0.6) and a significant contrast (signal-to-
noise ratio > 15.0) at equilibrium. The assay system was stable over a 48 hour period. 
Significantly, the assay is homogeneous and simple to implement for high-throughput 
screening compared to EMSA and ELISA. Overall, this FP assay offers a new way to 
identify and characterize novel molecules that inhibit STAT3:DNA association.
INTRODUCTION
STAT3, signal transducer and activator of 
transcription 3, is a key component in several signalling 
pathways [1, 2], is over-activated in approximately 70% of 
cancers [3] and plays critical roles in cell proliferation, cell 
survival, angiogenesis, immune invasion and metastasis 
[4]. Intensive efforts have been made over more than a 
decade to discover and develop small-molecule inhibitors 
to abate STAT3 activity through targeting its SH2 or 
transcriptional activation domains for the lowering 
of dimerization and activation of the protein [5–17]. 
During the discovery of STAT3 dimerization inhibitors, 
numerous cell-free and cell-based assays were developed 
to validate the inhibitory effect of selective inhibitors 
on dimerization. These include assays based on high-
throughput fluorescence polarization (FP) [10, 13, 15, 18], 
AlphaScreen™ [6, 7, 19], fluorescence resonance energy 
transfer (FRET) [6, 9, 20], enzyme-linked immunosorbent 
assays (ELISA) [21], cytoblot [5, 22, 23], and surface 
plasmon resonance (SPR) methodologies [8]. The FP, 
AlphaScreen™, ELISA and SPR assays are all applicable 
to high-throughput screening and are cell-free, while 
the remaining techniques are also applicable to high-
throughput approaches, and are cell-based. The application 
of these assays as screening platforms resulted in the 
discovery and validation of STAT3 dimerization inhibitors 
JSI-124 [5], bendamustine [6], piperlongumine [8] and 
static [10]. Moreover, the assays were also utilized as 
tools to support the discovery of other STAT3 dimerization 
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inhibitors such as STX-0119 [9], STA-21 [11] and LLL-12 
[12] which were all initially identified by in-silico high-
throughput screening, and additionally applied to LY5 
[13], shikonin derivatives [14], “Compound 9” [15], HJC-
1-30 [24] and HJC0123 [16] and FLLL32 [17] (Figure 
1) which were designed based on previously published 
chemical structures.
An understanding of the pathway for STAT3 
activation and the individual roles and functions of each 
STAT3 domain allows the targeting and subsequent 
attenuation of STAT3 activity in a specific and selective 
manner. STAT3 consists of six domains with different 
functions in the signal transduction pathway. The domain 
organization of the protein from the N- to C-terminus is 
as follows: the N-terminal domain (ND) which mediates 
the tetramerization of two STAT3 dimers when binding 
to the promoters of target genes [25, 26]; the coiled-coil 
domain responsible for interacting with other cytoplasmic 
proteins [27]; the DNA-binding domain (DBD) through 
which STAT3 binds to the promoter sequences of genes 
[28]; the linker domain which lies between the DNA-
binding and Src homology 2 (SH2) domains; the SH2 
domain which plays a role in dimer formation with another 
phosphorylated STAT3 monomer (via phosphotyrosine 
residue(s), (pY) in the transcriptional activation domain) 
for initial binding of STAT3 to DNA [29, 30]; and the 
transcriptional activation domain (TAD) at the C-terminus 
which includes the pY site(s) for facilitating STAT3 
dimerization and also is involved in the interactions 
with other nucleoplasmic proteins for the activation of 
transcription [31].
Although one STAT3 dimerization inhibitor (C188-
9) has advanced to early-phase clinical studies, it did not 
progress beyond this point [32], suggesting that preventing 
STAT3 dimerization through targeting the SH2 domain or 
TAD might be an intractable approach. Therefore, we and 
others have focused on inhibiting STAT3 DNA-binding 
through targeting the DBD. The small-molecule STAT3 
DBD inhibitor (inS3-54) was reported in the literature in 
2014, using an EMSA-based assay to determine inhibition 
of DNA-binding [33]. Other small-molecule STAT3 DBD 
inhibitors reported subsequently include additional inS3-
54 analogues [34], and niclosamide which was validated 
using ELISA [35] (Figure 2). Of the two approaches 
used in these studies, only ELISA is applicable to high-
throughput screening of compounds. Therefore, the 
development of a new orthogonal assay for discovering 
STAT3 DBD inhibitors would be desirable. Herein, we 
present an optimized high-throughput applicable FP assay 
for monitoring the STAT3:DNA association, referred to as 
Figure 1: STAT3 dimerization inhibitors. Published STAT3 dimerization inhibitors validated by at least one of the following assays: 
FP assay, AlphaScreen™ assay, cytoblot assay, FRET assay, SPR assay and ELISA.
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the STAT3127-688:DNA FP assay. In brief, this assay uses a 
soluble STAT3127-688 protein and a Bodipy-DNA conjugate 
as the fluorescent probe: the latter can be displaced by 
competitor ligands introduced during the experiment. The 
protocol is simple to implement compared to EMSA and 
ELISA, and there are no immobilised assay components, 
no addition of antibodies is required, and no washing 
procedures are involved, all of which impact on the time, 
cost and reliability of the assay.
RESULTS
Optimized preparations: STAT3127-688 target 
protein, and the Bodipy-DNA conjugate
To prepare the STAT3127-688 protein, an E. coli 
Rosetta strain was transformed with a recombinant 
pET-32a(+) plasmid containing the required STAT3 
sequence (encoding residues 127 to 688) lacking the 
ND and TAD. The expressed crude protein was isolated 
and stored at -20°C as pellets from ammonium sulphate 
precipitation. The crude protein was purified using ion-
exchange chromatography and the purified STAT3127-688 
was stored in the elution buffer (~200 mM NaCl, 1 mM 
dithiothreitol (DTT), 25 mM Tris pH 8.5). The conditions 
utilized in the subsequent STAT3127-688:DNA FP assays 
require the lowering of the salt and DTT concentrations 
by diafiltration using a 50 kDa concentrator to a final 
NaCl concentration < 200 μM. The purified protein was 
examined by SDS-PAGE and found to be composed of 
a single component with a molecular weight consistent 
with that expected for the construct (Supplementary 
Figure 1A). An additional centrifugation step using a 300 
kDa centrifugal filter removed misfolded, unfolded or 
aggregated STAT3127-688 that may impact on DNA binding 
[36], and provided a protein that gave more consistent FP 
responses (Figure 3).
The Bodipy-DNA conjugate was purchased in 
the form of two complementary single-stranded DNA 
(ssDNA) sequences that were annealed in a salt- and 
DTT-free buffer (25 mM Tris pH 8.5). Bodipy 650/665 
was selected as the fluorophore due to its relative 
insensitivity to pH changes and long absorption and 
emission wavelengths, which reduces the potential for 
fluorescence interference derived from aromatic small-
molecule inhibitors of the STAT3:DNA association.
Optimization assays: 20 nM Bodipy-DNA 
conjugate and 480 nM STAT3127-688
The optimal working concentration of the Bodipy-
DNA conjugate was determined in four separate FP 
experiments using either 1 nM, 10 nM, 20 nM, or 40 nM 
of the probe for titration against increasing STAT3127-688 
concentrations. When the data were fitted to a one site 
saturation binding model, a good fit was observed for 
the 20 nM and 40 nM Bodipy-DNA concentrations, 
but not for 1 nM and 10 nM concentrations (Figure 4). 
Accordingly, a 20 nM Bodipy-DNA concentration and a 
STAT3127-688 concentration of 480 nM (which gave 80% of 
the maximum FP response [37]) were selected for use in 
subsequent competition assays.
Competition experiments with unlabelled DNA 
sequences
To assess the displacement of the Bodipy-DNA 
conjugate, a 12-mer (12 base pair) unlabelled non-
Figure 2: STAT3 DBD inhibitors. Published STAT3 DBD inhibitors validated by at least one of the following assays: EMSA and 
ELISA.
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consensus DNA sequence or a 12-mer unlabelled 
consensus DNA sequence (identical to that of the Bodipy-
DNA conjugate) were applied as competitive inhibitors 
to displace the 12-mer Bodipy-DNA conjugate from 
STAT3127-688. The half-maximal inhibitory concentration 
(IC50) of the consensus DNA was determined as 0.30 ± 
Figure 3: FP versus STAT3127-688 concentration-response curves for 20 nM Bodipy-DNA conjugate applied with either 
filtered or unfiltered STAT3127-688. The response curve obtained by using unfiltered STAT3127-688 shows that low FP signals are detected 
when applying STAT3127-688 concentrations lower than 200 nM. The filtration of STAT3127-688 (300 kDa molecular weight cut-off filter) gave 
more consistent FP signal responses below 200 nM STAT3127-688 and an improved maximum FP signal. The NaCl concentration in each 
experiment was < 200 μM. R2 represents the coefficient of determination.
Figure 4: FP versus STAT3127-688 concentration-response curves for varying concentrations of the Bodipy-DNA 
conjugate. (A) 1 and 10 nM Bodipy-DNA conjugate; (B) 20 and 40 nM Bodipy-DNA conjugate. 20 nM was selected as the optimal 
Bodipy-DNA concentration.
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0.20 μM, while the non-consensus DNA gave an IC50 of 
2.3 ± 0.66 μM after 24 hr (Figure 5). Although the non-
consensus DNA was not expected to bind to STAT3127-
688, the result shows that there was an association but 
with a weaker binding affinity. This could be explained 
by non-specific binding due to electrostatic interactions 
between the DNA backbone and STAT3. This is consistent 
with previous observations that transcription factors can 
interact non-specifically with non-consensus sequences 
with lower binding affinities [38, 39].
The STAT3:DNA association is time-dependent
Before introducing small-molecule inhibitors into 
the assay, it is essential to understand the kinetics of the 
interaction between STAT3127-688 and the Bodipy-DNA 
conjugate. Therefore, the equilibrium association of 
STAT3127-688 (480 nM) and Bodipy-DNA (20 nM) was 
monitored after various incubation times. Our results show 
that after 14 hours, an equilibrium was reached that was 
stable for at least 48 hr (Figure 6). The length of time to 
reach equilibrium indicates slow binding kinetics between 
the two binding partners.
Reliability and signal-to-noise: Z’ values and S:N 
ratios
The suitability of the STAT3127-688:DNA FP assay 
for high-throughput screening was assessed by measuring 
the Z’ value (values 1 > Z’ ≥ 0.5 indicate a reliable assay 
[40]) and the signal-to-noise (S:N) ratio were determined 
at various incubation times (Table 1). Caution is required 
with interpreting the values of Z’ and S:N ratios after short 
incubation times (0 and 1 hr) as equilibrium is achieved 
after ≥ 14 hr. However, values determined after 14 hr are 
considered to be sufficiently robust to monitor competition 
between the Bodipy-DNA conjugate and inhibitors for the 
association with STAT3127-688.
Validation of the assay: inS3-54, inS3-54A18 and 
niclosamide are inhibitors of the STAT3:DNA 
association
To understand the applicability of the 
STAT3127-688:DNA FP assay in compound screening 
campaigns, a series of pilot competition studies were 
conducted with known STAT3 inhibitors. The STAT3 
Figure 5: Competitive inhibition of Bodipy-DNA-STAT3127-688 binding by consensus and non-consensus DNA sequences. 
The non-consensus DNA (self-complementary 5’-GTACCATGGTAC-3’) bound to the protein with a lower affinity than the consensus 
DNA (5’-ATTTCCCGTAAA-3’ and 5’-TTTACGGGAAAT-3’). Measurements were made after a 24 hr incubation at 4°C.
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DBD inhibitors, inS3-54, inS3-54A18 and niclosamide 
were tested along with STAT3 dimerization inhibitors, 
GpYLPQTV and HJC-1-30. GpYLPQTV is a peptide 
sequence derived from the gp130 subunit reported to bind 
to the STAT3 SH2 domain [18]. The activities of inS3-
54, inS3-54A18 and niclosamide were found to be dose- 
and time-dependent (time-dependent data not shown) 
as previously described [33–35]. Estimated IC50 values 
determined for inS3-54, inS3-54A18 and niclosamide 
were 21.3 ± 6.9 μM, 126 ± 39.7 μM and 219 ± 43.4 μM 
after 24 hr respectively (Figure 7). On the other hand, 
GpYLPQTV and HJC-1-30 were poor inhibitors of the 
STAT3:DNA association achieving only 50% and 70% 
inhibition respectively at 400 μM after incubation for 24 
hr (Figure 7).
The IC50 determination of the STAT3127-688:DNA 
FP assay is comparable to the protein 
electrophoretic mobility shift assay (PEMSA)
In order to confirm the binding behavior of selected 
ligands to the STAT3127-688 construct, we expressed and 
purified a recombinant yellow fluorescent protein YFP-
STAT3127-688fusion protein in the same manner as that for 
Figure 6: FP versus STAT3127-688 concentration-response curves after different incubation times. The FP signal was 
measured after incubation of 20 nM Bodipy-DNA conjugate and varying concentrations of STAT3127-688 for between 0 and 48 hr. The 
response curves show that the STAT3:DNA association reached equilibrium after 14 hr. A STAT3127-688 concentration of 480 nM gave 80% 
of the maximum FP response, which was selected for use in competition experiments.
Table 1: Calculated Z’ values and S:N ratios at various incubation times
Time course Z’ values S:N ratios
0 hr 0.53 9.16
1 hr 0.71 27.39
14 hr 0.63 20.06
24 hr 0.71 19.65
36 hr 0.72 19.16
48 hr 0.74 15.78
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STAT3127-688 which were adapted from the method used 
for a STAT3127-722 construct as previously described [41] 
(see Supplementary Materials and Methods). The purity of 
YFP-STAT3127-688 is shown in Supplementary Figure 1B. 
A protein electrophoretic mobility shift assay (PEMSA) 
[41], that is under further development in our labs using 
YFP-STAT3127-688 and the 12-mer unlabelled consensus 
DNA for STAT3, was carried out to give estimated IC50 
values for the inhibitors. The values for inS3-54 and inS3-
54A18 were ~26 μM and ~165 μM, respectively, after 24 
hr incubation at 4°C (Supplementary Figures 2 and 3), 
which are comparable to those determined by the FP assay 
(21.3 ± 6.9 μM, 126 ± 39.7 μM respectively).
DISCUSSION
Since STAT3 is highly involved in oncogenic 
pathways, there has been significant research directed 
towards finding inhibitors that interact with STAT3 or 
its upstream effectors. Identification of compounds that 
inhibit STAT3 dimerization has been a major focus. 
C188-9 has progressed to early-stage clinical trials [32], 
although it did not advance beyond this point. Recently, 
there has been an increased focus on blocking the 
interaction between STAT3 and DNA; however, the lack 
of direct binding assays has hindered structure-based drug 
design efforts in this area.
Consequently, we have developed a fluorescence 
polarization method to quantify STAT3 DNA-binding 
using a double-stranded DNA-fluorophore conjugate that 
has the consensus sequence 5’-TTNCNNNAA-3’[42] 
tethered to Bodipy at the 5’ end. The assay utilizes 
a STAT3127-688 construct, which lacks the Tyr705-
containing transactivation domain (TAD) that is involved 
in phosphorylation-mediated dimerization of STAT3 
and omits the N-terminal domain (ND) that is involved 
in tetramerization. Thus, the assay should be useful for 
identifying compounds that inhibit the STAT3:DNA 
association via binding to non-TAD/ND sites. The assay 
is a cell-free alternative to the EMSA and ELISA that have 
been applied previously in STAT3 DNA-binding inhibitor 
screening studies [33, 35]. This means that effects on 
upstream proteins or off-target effects on STAT3 cellular 
concentrations can be ruled out. The use of [32P] end-
labelled DNA, as is the case with EMSA, is avoided, and 
the use of recombinant STAT3 protein removes the need 
for cell nuclear extracts as a source of STAT3 protein 
which was utilized in the cell-based ELISA protocol as 
described by Furtek et al. [35].
The FP assay has some advantages in terms of 
throughput compared to ELISA and EMSA-based methods. 
Unlike EMSA, the FP-based experiments can be carried out 
in microtiter plates and are amenable to parallelization and 
automation. The assay is homogeneous unlike the ELISA 
method that requires washing steps and the measurement 
is direct, in contrast to ELISA that requires antibody-
mediated amplification of the readout. Additionally, 
the STAT3127-688:DNA FP assay described here, and the 
related STAT3-phosphopeptide FP technique utilizing 
FITC-GpYLPQTV as an SH2 domain-interactive probe 
(adapted from the method of Schust & Berg) [18] can be 
performed concurrently in two halves of the same 96-well 
black microtiter plate using suitable optical modules for 
each labelled probe (data not shown). Such an approach 
allows comparisons of the displacement of DNA and 
phosphopeptide fluorescent probes to be determined using 
the same protein construct, potentially allowing DBD and 
STAT3 dimerization inhibitors to be distinguished.
The applicability of the STAT3127-688:DNA FP assay for 
high-throughput screening was validated using previously 
Figure 7: Validation of the STAT3127-688:DNA FP competition assay using published STAT3 inhibitors. Percentage 
inhibition of Bodipy-DNA binding versus inhibitor concentration response curves for (A) STAT3 DBD inhibitors inS3-54, inS3-54A18 and 
niclosamide and (B) STAT3 dimerization inhibitors GpYLPQTV and HJC-1-30. Measurements were made after a 24 hr incubation at 4°C.
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described STAT3 DBD and dimerization inhibitors (Figures 5 
and 7). IC50 values determined after 24 hr were: inS3-54, 21.3 
± 6.9 μM; inS3-54A18, 126 ± 39.7 μM; and niclosamide, 
219 ± 43.4 μM (Figure 5). The binding affinities of inS3-
54 and S3-54A18 were further validated using the YFP-
STAT3127-688:DNA PEMSA that is under further development 
in our laboratories (Supplementary Figures 2 and 3). These 
values are not entirely consistent with those reported 
using cell-based assays using either the STAT3-dependent 
luciferase reporter assay (IC50 ~14 μM for inS3-54 and ~11 
μM for inS3-54A18) or the ELISA-based method (IC50 ~0.2 
μM for niclosamide) [32, 33, 35]. This raises the possibility 
that inS3-54 and inS3-54A18 may have additional activities 
in cells that contribute to the inhibition of STAT3-dependent 
luciferase reporter activity that warrant further investigation. 
A similar rationale may apply to niclosamide-treated HeLa 
cells from which nuclear extracts are taken for use in the 
ELISA-based detection of STAT3 activity [35].
The data support the use of the assay for 
characterizing both small molecule- and DNA-based 
competitors; the latter may be useful for quantifying the 
binding affinity of various consensus STAT3 binding 
sequences (Figures 5 and 7). The reliability of this FP 
assay was verified by the calculation of Z’ values and S:N 
ratios at time points up to 48 hr (Table 1). Refinement 
of the time-dependent activities of STAT3 inhibitors 
is possible; however, the slow association kinetics of 
STAT3127-688 and the Bodipy-DNA probe would need to be 
considered when carrying out such experiments (Figure 6).
Taken together, our STAT3127-688:DNA FP assay is 
a useful addition to the available assays for discovering 
STAT3 DBD inhibitors, because this assay is: 1) applicable 
to high-throughput screenings using both small molecule-
based and nucleic acid-based libraries in a multi-well 
plate format, 2) suitable for the validation of the inhibitory 
effect on the STAT3:DNA binding for inhibitors, 3) able to 
determine dose- and time-dependent activities of STAT3 
DBD inhibitors, 4) simple to conduct in comparison with 
the ELISA and EMSA methods, and 5) can be performed 
in parallel with the STAT3-phosphopeptide FP assay for 
discovering dimerization inhibitors on the same plate. 
In principle the assay methodology could be applied to 
other members of the STAT family of transcription factors 
including STAT1 and STAT5; both proteins have been 
cloned and expressed, and STAT1 has been co-crystallized 
with DNA facilitating the design of equivalent protein 
constructs for FP assays [43–45].
MATERIALS AND METHODS
Preparation of inS3-54, inS3-54A18, niclosamide, 
GpYLPQTV and HJC-1-30
Both inS3-54 and inS3-54A18 were synthesized 
using methods adapted from those described by Huang et al. 
[34]. The chemical structures of inS3-54 and inS3-54A18 
were confirmed by 1H NMR, 13C NMR and LC/MS and 
analytical purities of >95% were recorded (1H NMR and 
LC/MS). Niclosamide and GpYLPQTV were purchased 
in a powder form from Sigma-Aldrich and Generon, 
respectively. HJC-1-30 was provided by Dr Charlie Nichols. 
The inhibitors were dissolved in 100% DMSO to form stock 
solutions for the STAT3127-688:DNA FP assay.
Oligonucleotides
All oligonucleotide sequences were purchased 
from Eurofins as freeze-dried powders. The sequence 
of the unlabelled non-consensus DNA was self-
complementary 5’-GTACCATGGTAC-3’. The sequences 
of the Bodipy-DNA conjugate 5’-ATTTCCCGTAAA-3’ 
and 5’-TTTACGGGAAAT-3’ and the unlabelled 
consensus DNA are identical. The fluorophore, Bodipy 
650/665, was chemically linked to the 5’ end of 
5’-ATTTCCCGTAAA-3’. The Bodipy-DNA conjugate 
sequence was designed based upon M67 core sequence 
5’-TTCCCGTAA-3’[46], while the unlabelled non-
consensus DNA was designed to minimise similarity with 
the STAT3 consensus sequence 5’-TTNCNNNAA-3’ [42].
DNA annealing
The oligonucleotides were dissolved in the 
annealing buffer (25 mM Tris pH 8.5). An equal volume 
and concentration of each ssDNA was mixed in an 
Eppendorf tube that was then incubated at 95°C for 3 min, 
followed by cooling to room temperature overnight (in 
a 1 kg heatblock). This double-stranded DNA was then 
stored at -20°C. The Bodipy-DNA conjugate was prepared 
in the dark to prevent photoquenching of the fluorophore.
STAT3127-688 expression and purification
STAT3127-688 expression was conducted as previously 
described [41]. One day before the STAT3127-688:DNA FP 
assay was performed, the ammonium sulphate-precipitated 
crude protein pellet was re-suspended using a solution of 
1 mM DTT 25 mM Tris pH 8.5 and purified using HiTrap 
QFF columns (GE Healthcare) coupled to a fast protein 
column chromatography (FPLC) instrument (NGC™ 
Chromatography Systems, Bio-Rad). The elution of the 
STAT3127-688protein was conducted using a solution of 1 mM 
DTT and 25 mM Tris pH 8.5, and a gradient of increasing 
NaCl concentration. The purified STAT3127-688 usually eluted 
at 200 mM NaCl and was collected in a 96-well block. The 
purified STAT3127-688 was stored in the eluent at 4°C. The 
purity of STAT3127-688 was determined using SDS-PAGE.
Preparation of the STAT3127-688 sample for the 
STAT3127-688:DNA FP assay
On the day the STAT3127-688:DNA FP assay 
was performed, the STAT3127-688 protein sample was 
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prepared immediately for use, usually at 0.4 mg/ml. 
Buffer exchange was performed at least three times 
by diafiltration conducted using a 50 kDa centrifugal 
concentrator (Sartorius). The residual STAT3127-688 protein 
solution was diluted 10-fold with diafiltration buffer, 25 
mM Tris pH 8.5, upon completion of each diafiltration 
step. Aggregated STAT3127-688 was removed using a 
benchtop centrifuge if aggregation was observed on visual 
inspection of the samples. Finally, invisible STAT3127-688 
aggregate was removed from the sample by centrifugation 
through a 300 kDa centrifugal filter (Sartorius) at ~800 g.
Conduct of the STAT3127-688:DNA FP assay
The FP assay was conducted in 96-well Chimney 
Well black microtiter plates (Greiner Bio-One). The final 
concentration of FP buffer was composed of 5% glycerol, 
20 mM Tris pH 8.5, 1 mM EDTA, 0.01 mg/ml bovine 
serum albumin, 4% DMSO, with or without 480 nM 
purified STAT3127-688, 20 nM Bodipy-DNA conjugate, with 
or without a variable concentration of inhibitor, to make 
a total volume of 100 μl per well. After the addition of all 
assay components, the plates were incubated and gently 
agitated for the first hour at room temperature, followed 
by further incubation at 4°C. During incubation, the plates 
were covered with black lids to protect the samples from 
light and to reduce evaporation of the FP buffer solution. 
The plates were read at various incubation times using an 
FP plate reader (PHERAstar, BMG Labtech) with an FP 
590-675-675 optical module (BMG Labtech).
Calculations of Z’ value and S:N ratio
The Z’ values were calculated using the equation Z’ = 
1 - (3SDbound + 3SDfree)/(mean of mPbound – mean of mPfree), 
where the SD is the standard deviation of the measurements 
and the mP is the measured fluorescence polarization [40]. 
The mP was automatically calculated by the FP plate reader 
using the equation mP = (I
║
−I
┴
)/(I
║
+I
┴
) where I
║
 and I
┴
 are 
the fluorescence polarization intensities of the Bodipy-DNA 
conjugate with polarizations parallel and perpendicular 
to the incident light, respectively. The bound state was 
determined by incubating 20 nM Bodipy-DNA conjugate 
with 480 nM STAT3127-688 protein, whereas for the free state, 
the same mixture was incubated with an additional 10 μM 
of unlabelled consensus DNA as a competitor. The equation 
S:N = (mean of mPbound – mean of mPfree)/(SDbound
2 + SDfree
2)0.5 
was utilized to determine the signal-to-noise ratios [47].
Analytical methodology
Each assay condition was evaluated with at least 
three repeats. Binding curves were fitted using SigmaPlot 
13 using the ‘one site saturation’ and ‘sigmoidal dose-
response (variable slope)’ non-linear regression curve-
fitting functions. The ‘one site saturation’ model uses the 
equation y = (Bmaxx)/(KD+ x), where Bmax is the maximal 
FP response and KD is the dissociation constant. The 
‘sigmoidal dose-response (variable slope)’ utilizes the 
equation y = min + (max – min)/(1 + 10b(logIC50 - x)), where 
max and min represents the maximum and minimum 
response plateaus respectively, and b is the Hill slope for 
the binding event. The error bars shown in the graphs are 
SDs from the mean values of the replicates.
Abbreviations
12-mer, 12 base pair; DBD, DNA-binding 
domain; DTT, dithiothreitol; ELISA, enzyme-linked 
immunosorbent assay; EMSA, electrophoretic mobility 
shift assay; FP, fluorescence polarization; FRET, 
fluorescence resonance energy transfer; ND, N-terminal 
domain; PEMSA, protein electrophoretic mobility 
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transducer and activator of transcription 3; STAT3127-688, 
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